Bavaria: CSU and Free Voters want to get more pharmaceutical production

Munich (dpa / lby) - The state parliamentary groups of the Bavarian governing parties CSU and Free Voters are campaigning for more pharmaceutical research and additional production of medicines in Germany and the EU countries.

Bavaria: CSU and Free Voters want to get more pharmaceutical production

Munich (dpa / lby) - The state parliamentary groups of the Bavarian governing parties CSU and Free Voters are campaigning for more pharmaceutical research and additional production of medicines in Germany and the EU countries. The production of important medicines should not take place exclusively in third countries, said the health policy spokesman for the CSU parliamentary group, Bernhard Seidenath, on Monday in Munich. "We have to bring production back into Europe," he emphasized.

For this reason, the two government factions have put together a package of applications that is to be debated and approved in the state parliament. Among other things, it stipulates that the statutory health insurance companies should take domestic production into account when concluding discount agreements. Research into medical products in Germany and Europe is also to be strengthened. The focus here has shifted massively towards Asia in the past ten years.

Seidenath said that within Europe, antibiotics are only produced at one location in Austria - everything else comes from China and India to Germany. There are always bottlenecks in patient care. The CSU MP Beate Merk emphasized that the drug tamoxifen, important in the care of patients with hormone-related breast cancer, was no longer available at times. Even antipyretics for children cannot always be delivered because the manufacturers have temporarily shut down production for cost reasons.

"Germany was once the world's pharmacy," said the state government's care officer, Peter Bauer (Freie Wahler). The draft for a new law at federal level to relieve the statutory health insurance companies is leaving the research-based pharmaceutical companies out in the rain.